Coya Therapeutics
Update in progressCOYA (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Coya Therapeutics is a clinical-stage biotech focused on enhancing regulatory T cells (Tregs). Its lead program, COYA 302, is a subcutaneous biologic designed to boost Treg function while reducing effector T cells and activated macrophages, in Phase 2 for ALS and under exploration for FTD, AD, and PD. Preclinical programs include COYA 301 (low-dose IL-2 for AD), COYA 303 (IL-2 plus GLP-1 receptor agonist), and Treg-derived exosomes COYA 201/206 and COYA 101. Based in Houston, TX.
Company score
- Sentiment
- 0.32
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.30
- Governance
- 0.13
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.12
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.22
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!